投資
14投資退出
3基金
1想告知投資者類似腋資本關於你的公司嗎?
提交你的分析師簡報在投資者麵前,CB Insights的平台上的客戶和合作夥伴。188bet游戏
最新的腋資本新聞
2021年7月14日
Suono生物有限公司宣布超額認購資金輪腋資本和瑞穗證券首席投資的福克斯,質量。,July 13, 2021-- Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, today announced it has raised an $8.5 million Series A financing led by Axil Capital and Mizuho Securities Principal Investment, with participation by Taiwania Capital and other investors. Suono Bio will utilize the funds to advance its lead programs in inflammatory bowel disease as well as expansion of its pipeline. Suono Bios platform technology enables the rapid, targeted delivery of drugs, including gene therapies, for the first time, enabling the use of the right drug in the right patient. Suono Bio leverages technology developed in the laboratory of Institute Professor Robert Langer at the Massachusetts Institute of Technology (MIT) to facilitate rapid, local administration of therapeutics to treat serious diseases. The company was founded by Professor Langer, Professor Giovanni Traverso, from the Department of Mechanical Engineering at MIT and a gastroenterologist and biomedical engineer at Brigham and Womens Hospital, Harvard Medical School, and Dr. Carl Schoellhammer. Publications on the technology have appeared in Nature, Gastroenterology, and Science Translational Medicine, and the company has previously announced strategic investments from FUJIFILM Corporation and NGK Spark Plug Co., LTD. Suono Bios technology is poised to accelerate novel therapeutics to the clinic by finally overcoming the challenges with delivering drugs like DNA or RNA, said Frederick Shane, Managing Partner of Axil, who joined the Board of Directors. Their technology spans beyond a single product or asset to a whole new platform of products to treat debilitating diseases and we are thrilled to lead this round, he added. We are thrilled to have marquee investors involved with Suono Bio and speaks to the rapid pace with which the team has taken a conceptual technology from Prof. Langers lab and operationalized it to address pressing health issues, said Scott Kellogg, CEO. Proceeds from the Series A financing will allow completion of the development of the companys first product for treating ulcerative colitis, readying it for human trials, and further the development of the overall technology platform. The ability to deliver macromolecules, including DNA and RNA based medicines outside of the liver and in a formulation-independent approach could be applied to many diseases and benefit a tremendous number of patients, said Professor Robert Langer, co-founder and Board Member. We are excited to be able to advance the development of an approach which has the capacity to rapidly and effectively deliver a broad array of therapeutics from small molecules to nucleic acids, added Professor Giovanni Traverso, co-founder and Board Member. ABOUT SUONO BIO Suono Bio is developing therapeutic products for inflammatory-mediated diseases leveraging their ultra-rapid and formulation independent delivery technology. Suono Bios platform was developed at The Massachusetts Institute of Technology in Professor Robert Langers laboratory and enables rapid, localized delivery of small molecules, biologics, and nucleic acids and gene therapies without the need for encapsulation of the therapeutic. For more information, please visit www.suonobio.com. ABOUT AXIL CAPITAL Axil Capital Partners is a Tokyo based venture capital firm specializing in biomedical & healthcare technology investments with an emphasis on supporting the growth of early-stage ventures. The firm invests in a wide range of companies in the life sciences space, with a particular focus on cross-disciplinary technologies that can transform the future of healthcare. For more information, please visit https://www.axilcapital.com/. Contact:
腋資本投資
14投資
腋資本了14投資。他們最新的投資Cellusion作為他們的一部分C係列在2023年6月6日。
腋資本投資活動
日期 |
輪 |
公司 |
量 |
新的嗎? |
共同投資者 |
來源 |
---|---|---|---|---|---|---|
6/7/2023 |
C係列 |
Cellusion |
20.3美元 |
是的 |
3 |
|
6/11/2021 |
一個係列 |
Aibios |
7.02美元 |
沒有 |
2 |
|
3/25/2021 |
一個係列 |
Suono生物 |
8.5美元 |
是的 |
腋資本,Catalio資本管理,JDRF近年來基金,瑞穗證券首席投資,Taiwania資本,和未披露的投資者 |
3 |
3/3/2021 |
B係列 |
|||||
11/10/2020 |
B係列 |
日期 |
6/7/2023 |
6/11/2021 |
3/25/2021 |
3/3/2021 |
11/10/2020 |
---|---|---|---|---|---|
輪 |
C係列 |
一個係列 |
一個係列 |
B係列 |
B係列 |
公司 |
Cellusion |
Aibios |
Suono生物 |
||
量 |
20.3美元 |
7.02美元 |
8.5美元 |
||
新的嗎? |
是的 |
沒有 |
是的 |
||
共同投資者 |
腋資本,Catalio資本管理,JDRF近年來基金,瑞穗證券首席投資,Taiwania資本,和未披露的投資者 |
||||
來源 |
3 |
2 |
3 |
腋資本基金的曆史
1基金曆史
腋資本有1 基金,包括腋生命科學和醫療基金。
截止日期 |
基金 |
基金類型 |
狀態 |
量 |
來源 |
---|---|---|---|---|---|
|
腋生命科學和醫療基金 |
|
|
|
1 |
截止日期 |
|
---|---|
基金 |
腋生命科學和醫療基金 |
基金類型 |
|
狀態 |
|
量 |
|
來源 |
1 |
腋資本團隊
2團隊成員
腋資本有2 團隊成員,包括當前的管理合夥人,弗雷德·謝恩。
的名字 |
工作經曆 |
標題 |
狀態 |
---|---|---|---|
弗雷德肖恩 |
|
管理合夥人 |
當前的 |
的名字 |
弗雷德肖恩 |
|
---|---|---|
工作經曆 |
|
|
標題 |
管理合夥人 |
|
狀態 |
當前的 |
發現正確的解決方案為您的團隊
CB見解188bet游戏科技市場情報平台分析數百萬數據點在供應商、產品、合作關係,專利來幫助您的團隊發現他們的下一個技術解決方案。